Live · TradingView
Back to the NewsWire

Mindmedicinelaw

Published September 7, 2026 · Updated September 8, 2026

Metabolomic Insights from Bio-K/NNDC IV Ketamine Trial in TRD - The Psychedelic Journal

The Bio-K/NNDC multicenter trial offers the most detailed metabolomic profile of IV racemic ketamine in treatment-resistant depression to date,.

Read the full story at Mindmedicinelaw

Surfaced by this Google Alert

  • Ketamine